Lonza enters licensing agreement to help produce arGEN-X antibodies
The license secures access for arGEN-X and its strategic partners to Lonza’s proprietary GS Xceed System for the creation and development of cell lines to be utilized in the manufacture of biopharmaceuticals.
Previously, Lonza manufactured two of arGEN-X’s clinical-stage proprietary therapeutic antibodies, as well as a third program due to commence clinical trials in 2015. Under the new agreement, arGEN-X has access to the GS Xceed System for the development and manufacture of both current and future therapeutic antibody products.
“The initiation of the multi-product GS Xceed License Agreement allows both companies the flexibility to move forward to commercial production of arGEN-X products,” said Karen Fallen, VP Head of Licensing, Lonza Custom Development Services.
The GS Xceed System is Lonza’s latest for mammalian protein expression, offering reduced cell line construction timelines and increased product yields.
“The multi-product license strengthens the competitive positioning of our products and those of our sublicensees by optimizing the pharmacoeconomics of the antibody development process,” said Tim Van Hauwermeiren, CEO of arGEN-X.
